Peer-reviewed Phase 3 data on MDMA-assisted massed exposure therapy for PTSD will be published in a indexed journal by September 15, 2026.

A peer-reviewed scientific journal will publish the full results of a large Phase 3 clinical trial (the final stage before approval) testing MDMA with a new compressed treatment schedule for PTSD by September 15, 2026. This matters because it shows whether the new, faster way of delivering MDMA therapy actually works — which could influence whether the FDA approves it.

Massed format trials address prior treatment-duration objections and multi-site data convergence is reportedly strong. Publication is a discrete, verifiable event in a named journal with a clear date. Confidence trimmed from source estimate to account for publication scheduling uncertainty and possible embargo delays.